Government Funding

Canadian federal health research funder with direct psilocybin psychotherapy trial grants.

U.S. federally directed defense-health research program office administering targeted grants, including mental-health priorities.

US defense research funder with psychedelic-informed neuropsychiatric R&D (Focused Pharma).

EU supranational research funding framework supporting psilocybin clinical research (PsyPal).

Funds frontier research across all fields of science and scholarship in Europe. ERC Starting / Consolidator / Advanced Grants have supported multiple psychedelic neuroscience projects.

French National Institute of Health and Medical Research (INSERM), a national public biomedical research organization with active discourse and research engagement on psychedelic medicine.

Australian Government medical research funder with explicit psychedelic trial grants (including ketamine, psilocybin, and MDMA).

NIH institute funding psychedelic oncology-adjacent mental health research, including psilocybin therapy studies for advanced cancer-related distress.

NIH institute funding psychedelic clinical research, including psilocybin-assisted psychotherapy protocols in depression and chronic pain populations.

The National Health and Medical Research Council is the Australian Government body for health and medical research funding, evidence guidance, and research ethics. It is tracked here as a public funder for Australian clinical research.

UK public health research funder with NIHR-backed psilocybin addiction trial funding.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

NIH institute funding neuroscience projects involving psychedelics, including psilocybin-related chronic pain and neuroplasticity investigations.

NIH institute with co-funded psychedelic research activity, including projects on psychedelics for older adults with chronic pain.

NIH institute funding psychedelic-related alcohol use disorder research, including psilocybin-assisted treatment and derivative development projects.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

The SNSF funds basic and applied research across Switzerland. Funds notable psychedelic research at Swiss universities and hospitals (Basel, Zurich, Geneva).

The state public health agency for Texas, responsible for promoting and protecting the health of Texans through disease prevention, health promotion, and oversight of public health services. The agency licenses healthcare facilities, monitors communicable diseases, and supports mental health and substance use programs.

Texas state health agency overseeing policy functions and implementation of psychedelic-adjacent public initiatives such as ibogaine programs.

U.S. Army medical R&D command supporting military biomedical research and administration pathways connected to DoD psychedelic clinical trial funding.

U.S. federal veterans health authority with explicit psychedelic-adjacent clinical research and care-implementation activity through VA research and care networks.

UKRI is the UK government's research funding body. Includes the Medical Research Council (MRC) and Engineering and Physical Sciences Research Council (EPSRC), both relevant to psychedelic and related research.

ARPA-H is the US federal agency for high-risk, high-reward biomedical research. Launched the EVIDENT initiative in 2025 (total $139.4M, ≥$50M earmarked for psychedelic research for serious mental illness) to validate and innovate behavioral-health therapeutics including psilocybin and related compounds.

The NSF funds basic science research across the US, including neuroscience and pharmacology projects relevant to psychedelic mechanisms.

Federal defense department overseeing military health R&D and psychedelic-related clinical trial funding via DHA/DMRDP implementation.

Naval Medical Center San Diego (NMCSD) is the US Navy’s largest hospital on the West Coast, providing medical care to active-duty military personnel, retirees, and their families. Its Department of Psychiatry participates in clinical trials investigating MDMA-assisted and psilocybin-assisted therapies for PTSD and depression in service members, contributing to the DoD’s expanding psychedelic research program.

The VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.

The VA Puget Sound Health Care System serves veterans across the Pacific Northwest with major facilities in Seattle and Tacoma, Washington. As part of the VA’s expanding psychedelic research program, it participates in clinical trials examining MDMA-assisted therapy and psilocybin for PTSD and depression in veterans.

Vancouver Island Health Authority (Island Health) is a publicly funded regional health authority serving Vancouver Island and surrounding communities in British Columbia, Canada. Island Health operates hospitals, mental health services, and community health programs for over 800,000 residents, and supports clinical research including innovative approaches to psychedelic-assisted mental health treatment.

Västra Götalandsregionen (Region Västra Götaland) is the regional government and public health authority for western Sweden, including the Gothenburg metropolitan area and surrounding counties. With 1.7 million residents served by 17 hospitals and over 50,000 employees, it is one of Sweden's largest public employers and a major supporter of clinical psychiatric research.

Walter Reed National Military Medical Center (WRNMMC) is the United States' premier military medical center, located in Bethesda, Maryland and operated jointly by the Army and Navy. It provides advanced medical care to active duty service members, veterans, retirees, and their families, and conducts clinical research on PTSD, traumatic brain injury, and emerging treatments for military personnel.

The World Health Organization (WHO) is the United Nations' specialized agency for international public health, founded in 1948 and headquartered in Geneva, Switzerland. WHO sets global health standards, coordinates disease surveillance, and provides technical guidance on mental health, substance use disorders, and the international scheduling of controlled substances including psychedelics.

ZonMw (The Netherlands Organisation for Health Research and Development) is a Dutch government organization that funds and steers health research and healthcare innovation on behalf of the Ministry of Health, Welfare and Sport and the Dutch Research Council (NWO). ZonMw finances studies across all healthcare domains including mental health, substance use disorders, and novel therapeutic approaches such as psychedelic-assisted therapy.